VYNE Company Profile and Key Details

Q: Who are the executives of VYNE?

Dr. Iain A. Stuart Ph.D.Chief Scientific OfficerMr. David SchuzSenior Vice President of Intellectual PropertyMr. Tyler ZerondaChief Financial Officer & TreasurerDr. Darrell S. Rigel M.S., M.D., MSConsultantMs. Mutya Harsch J.D.Gen. Counsel, Chief Legal Officer & Company Sec.Dr. Russell Elliott D.Phil.Senior Vice President of Pharmaceutical Devel.Mr. David T. DomzalskiChief Executive Officer, Pres & Director

NASDAQ : VYNE

VYNE Therapeutics

$28.56

At Close 4:00 PM

Not Actively Trading

58.55

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

VYNE Therapeutics Inc. (VYNE) stock remained unchanged at $28.56 a share on NASDAQ. The stock opened at $25.50, fluctuating between $23.37 to $28.72 during the session.

Stock Snapshot

28.56

Prev. Close

19.07M

Market Cap

23.37

Day Low

-43.27272727272727

P/E Ratio

-0.66

EPS (TTM)

-0.82

Cash Flow per Share

25.5

Open

667.7K

Number of Shares

28.72

Day High

81.75%

Free Float in %

2.86

Book Value

93.26K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Aug 12, 2026	43.89	44.00	41.73	42.77	11.18K
Aug 11, 2026	42.01	42.32	41.98	41.98	1.43K
Aug 07, 2026	42.06	44.28	41.12	41.43	23.68K
Jul 27, 2026	25.50	28.56	23.37	28.56	93.28K
Jul 24, 2026	24.34	27.44	23.50	25.45	55.27K
Jul 23, 2026	43.72	46.95	40.91	46.17	19.35K
Jul 22, 2026	42.76	45.50	42.50	44.88	24.11K
Jul 21, 2026	39.20	44.95	38.90	44.64	106.27K
Jul 20, 2026	38.50	40.87	37.75	40.39	44.51K
Jul 17, 2026	38.00	39.00	37.06	38.05	19.92K
Jul 16, 2026	37.34	39.48	37.27	38.38	29.55K
Jul 15, 2026	35.80	38.75	35.80	37.86	43.06K
Jul 14, 2026	32.50	36.00	32.50	35.55	28.28K
Jul 13, 2026	31.75	34.60	31.75	32.90	58.16K
Jul 10, 2026	31.50	32.90	30.62	31.88	319.39K
Jul 09, 2026	32.33	33.95	32.33	33.60	541.26
Jul 08, 2026	32.51	33.33	31.66	32.51	443.94
Jul 07, 2026	33.20	33.50	32.40	33.49	1.02K
Jul 06, 2026	34.23	34.23	32.57	33.38	1.71K
Jul 02, 2026	34.00	34.50	33.50	34.00	10.35K

Contact Details

Stewartsville, NJ 08807

United States

https://vynetherapeutics.com 800 775 7936

About Company

VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.

Stock Peers

ARGX

-2.73-0.28%

argenx SE$959.49 REGN

-7.98-1.00%

Regeneron Pharmaceuticals, Inc.$788.04 VRTX

3.81+0.73%

Vertex Pharmaceuticals Incorporated$526.19 MDGL

3.35+0.65%

Madrigal Pharmaceuticals, Inc.$516.56 UTHR

3.24+0.69%

United Therapeutics Corporation$475.45 ONC

0.88+0.24%

BeOne Medicines AG$360.85 KRYS

0.86+0.25%

Krystal Biotech, Inc.$345.82 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

2.48+0.83%

Ligand Pharmaceuticals Incorporated$301.52 PRAX

-1.01-0.36%

Praxis Precision Medicines, Inc.$280.78

Frequently Asked Questions

What is the current VYNE Therapeutics Inc. (VYNE) stock price?

VYNE Therapeutics Inc. (NASDAQ: VYNE) stock price is $28.56 in the last trading session. During the trading session, VYNE stock reached the peak price of $28.72 while $23.37 was the lowest point it dropped to. The percentage change in VYNE stock occurred in the recent session was 0% while the dollar amount for the price change in VYNE stock was $0.00.

VYNE's industry and sector of operation?

The NASDAQ listed VYNE is part of Biotechnology industry that operates in the broader Healthcare sector. VYNE Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of VYNE?

Dr. Iain A. Stuart Ph.D.
Chief Scientific Officer
Mr. David Schuz
Senior Vice President of Intellectual Property
Mr. Tyler Zeronda
Chief Financial Officer & Treasurer
Dr. Darrell S. Rigel M.S., M.D., MS
Consultant
Ms. Mutya Harsch J.D.
Gen. Counsel, Chief Legal Officer & Company Sec.
Dr. Russell Elliott D.Phil.
Senior Vice President of Pharmaceutical Devel.
Mr. David T. Domzalski
Chief Executive Officer, Pres & Director

How VYNE did perform over past 52-week?

VYNE's closing price is 103.64% higher than its 52-week low of $14.03 where as its distance from 52-week high of $74.47 is -61.65%.

How many employees does VYNE have?

Number of VYNE employees currently stands at 10.

Link for VYNE official website?

Official Website of VYNE is: https://vynetherapeutics.com

How do I contact VYNE?

VYNE could be contacted at phone 800 775 7936 and can also be accessed through its website. VYNE operates from P.O. Box 125, Stewartsville, NJ 08807, United States.

How many shares of VYNE are traded daily?

VYNE stock volume for the day was 93.26K shares. The average number of VYNE shares traded daily for last 3 months was 16.91K.

What is the market cap of VYNE currently?

The market value of VYNE currently stands at $19.07M with its latest stock price at $28.56 and 667.7K of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	10
Beta	2.01
Sales or Revenue	$424.00K
5Y Sales Change%	-0.999%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	10
Beta	2.01
Sales or Revenue	$424.00K
5Y Sales Change%	-0.999%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

VYNE Company Profile and Key Details

VYNE Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Key Takeaways

Company Overview

Price Forecast & Outlook

Valuation Metrics